Abstract:The study of modified RNA known as epitranscriptomics has become increasingly relevant in our understanding of disease-modifying mechanisms. Methylation of N6 adenosine (m6A) and C5 cytosine (m5C) bases occur on mRNAs, tRNA, mt-tRNA, and rRNA species as well as non-coding RNAs. With emerging knowledge of RNA binding proteins that act as writer, reader, and eraser effector proteins, comes a new understanding of physiological processes controlled by these systems. Such processes when spatiotemporally disrupted within cellular nanodomains in highly specialized tissues such as the brain, give rise to different forms of disease. In this review, we discuss accumulating evidence that changes in the m6A and m5C methylation systems contribute to neurocognitive disorders. Early studies first identified mutations within FMR1 to cause intellectual disability Fragile X syndromes several years before FMR1 was identified as an m6A RNA reader protein. Subsequently, familial mutations within the m6A writer gene METTL5, m5C writer genes NSUN2, NSUN3, NSUN5, and NSUN6, as well as THOC2 and THOC6 that form a protein complex with the m5C reader protein ALYREF, were recognized to cause intellectual development disorders. Similarly, differences in expression of the m5C writer and reader effector proteins, NSUN6, NSUN7, and ALYREF in brain tissue are indicated in individuals with Alzheimer's disease, individuals with a high neuropathological load or have suffered traumatic brain injury. Likewise, an abundance of m6A reader and anti-reader proteins are reported to change across brain regions in Lewy bodies diseases, Alzheimer's disease, and individuals with high cognitive reserve. m6A-modified RNAs are also reported significantly more abundant in dementia with Lewy bodies brain tissue but significantly reduced in Parkinson's disease tissue, whilst modified RNAs are misplaced within diseased cells, particularly where synapses are located. In parahippocampal brain tissue, m6A modification is enriched in transcripts associated with psychiatric disorders including conditions with clear cognitive deficits. These findings indicate a diverse set of molecular mechanisms are influenced by RNA methylation systems that can cause neuronal and synaptic dysfunction underlying neurocognitive disorders. Targeting these RNA modification systems brings new prospects for neural regenerative therapies.

The Role of RNA m5C Modification in Central Nervous System Diseases

RNA 5-Methylcytosine Modification: Regulatory Molecules, Biological Functions, and Human Diseases

Advances in RNA Cytosine-5 Methylation: Detection, Regulatory Mechanisms, Biological Functions and Links to Cancer

RNA 5-Methylcytosine Modification and Its Emerging Role As an Epitranscriptomic Mark.

RNA methylation in neurodevelopment and related diseases

The role of m5C methyltransferases in cardiovascular diseases

m6A modification and its role in neural development and neurological diseases

Biological roles of RNA m5C modification and its implications in Cancer immunotherapy

Dysregulation of RNA modification systems in clinical populations with neurocognitive disorders

The role of m<SUP>6</SUP>A modification in physiology and disease

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

The Roles of M6a RNA Modifiers in Human Cancer

Deciphering the vital roles and mechanism of m5C modification on RNA in cancers

The role of m6A modification in physiology and disease

The role of m6A modification in the biological functions and diseases

m6A methylation: Critical roles in aging and neurological diseases

The Role of N6-methyladenosine Modification in Neurodegenerative Diseases

Multifaceted Functions of RNA m6A Modification in Modulating Regulated Cell Death

N6-methyladenosine RNA modification: A promising regulator in central nervous system injury

N6-methyladenosine and Neurological Diseases